Pharmacologic class (EPC) · 5 drug pages

Nondepolarizing neuromuscular blocker: adverse event reports filed with FDA

9,444 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

9,444
reports across the class: 0.1% of all reports; 1,271
reports, 12 months to June 2026: 773 in the 12 months before; 90%
marked serious by the reporter: 57.4% across all reports; 5
drugs with a page: brand and generic names counted separately

Nondepolarizing neuromuscular blocker is a pharmacologic class (an FDA Established Pharmacologic Class) with 5 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 9,444 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026.

1,271 reports arrived in the 12 months to June 2026, up 64% from 773 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 90% of the class's reports are marked serious, 6.9% record death among the outcomes and 30.2% record hospitalisation, as reported.

Across the class the reactions recorded most often are anaphylactic reaction (12.8%), anaphylactic shock (10.9%) and drug ineffective (10.4%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Rocuronium bromide	generic	4,046	517	83%	Drug ineffective
Rocuronium	generic	3,358	628	96.2%	Anaphylactic reaction
CisatracuriumCisatracurium besylate	brand	786	53	98.5%	Off label use
Vecuronium bromide	generic	743	31	86.9%	Drug ineffective
Atracurium besylate	generic	511	42	96.9%	Anaphylactic shock

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Anaphylactic reactiona severe, sudden allergic reaction12.8%1,212
Anaphylactic shocka severe allergic reaction with collapse10.9%1,030
Drug ineffectivethe medicine did not work as expected10.4%980
Hypotensionlow blood pressure9.6%905
Cardiac arrestthe heart stopped5.6%525
Tachycardiafast heart rate3.8%363
Bronchospasmtightening of the airways3.6%342
Bradycardiaslow heart rate3.5%328
Drug interactionan interaction between medicines3.1%294
Urticariahives2.9%274
Off label useused for a purpose or in a way not on the label2.9%271
Rashskin rash2.8%266
Anaesthetic complication neurological2.8%260
Oxygen saturation decreased2%193
Circulatory collapsecollapse of the circulation2%189
Foetal exposure during pregnancythe unborn baby was exposed to the medicine2%187
Hypoxialow oxygen1.9%183
Condition aggravatedthe condition being treated got worse1.8%167
Hyperthermia malignant1.7%165
Erythemaskin redness1.7%161
Respiratory failurethe lungs could not supply enough oxygen1.6%148
Neuromuscular block prolonged1.5%146
Premature babya baby born early1.5%140
Maternal exposure during pregnancythe mother took the medicine during pregnancy1.4%129
Blood pressure decreaseda low blood pressure reading1.3%124

Solid bar: share of all class reports. Hollow bar: the median share across the 5 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death6.9%649

Life-threatening29.2%2,759

Hospitalisation (initial or prolonged)30.2%2,856

Disability1.3%123

Congenital anomaly0.4%40

Other serious57.8%5,459

Not serious10%941

Patient age

Under 22.7%255

2 to 112.5%239

12 to 172.4%228

18 to 4421.1%1,990

45 to 6425.3%2,390

65 to 7412.8%1,205

75 and over7.9%746

Age not given25.3%2,391

Who reported

Physician34.9%3,294

Pharmacist13.1%1,239

Other health professional41%3,872

Lawyer0.1%5

Consumer or non-health professional5.4%511

Not given5.5%523

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Nondepolarizing neuromuscular blocker reports

Which drugs are in the Nondepolarizing neuromuscular blocker class on this site?

Rocuronium bromide, Rocuronium, Cisatracurium, Vecuronium bromide and Atracurium besylate. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

9,444 reports through June 2026, 1,271 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

anaphylactic reaction (12.8%), anaphylactic shock (10.9%), drug ineffective (10.4%), hypotension (9.6%) and cardiac arrest (5.6%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.